Cargando…

Identification and Characterization of a New Platinum-Induced TP53 Mutation in MDAH Ovarian Cancer Cells

Platinum-based chemotherapy is the therapy of choice for epithelial ovarian cancer (EOC). Acquired resistance to platinum (PT) is a frequent event that leads to disease progression and predicts poor prognosis. To understand possible mechanisms underlying acquired PT-resistance, we have recently gene...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lorenzon, Ilaria, Pellarin, Ilenia, Pellizzari, Ilenia, D’Andrea, Sara, Belletti, Barbara, Sonego, Maura, Baldassarre, Gustavo, Schiappacassi, Monica
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2019
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7016977/ https://www.ncbi.nlm.nih.gov/pubmed/31877751 http://dx.doi.org/10.3390/cells9010036

Ejemplares similares

Splicing factor proline- and glutamine-rich (SFPQ) protein regulates platinum response in ovarian cancer-modulating SRSF2 activity
por: Pellarin, Ilenia, et al.
Publicado: (2020)

Common biological phenotypes characterize the acquisition of platinum-resistance in epithelial ovarian cancer cells
por: Sonego, Maura, et al.
Publicado: (2017)

CDK6 protects epithelial ovarian cancer from platinum‐induced death via FOXO3 regulation
por: Dall'Acqua, Alessandra, et al.
Publicado: (2017)

Serum- and glucocorticoid- inducible kinase 2, SGK2, is a novel autophagy regulator and modulates platinum drugs response in cancer cells
por: Ranzuglia, Valentina, et al.
Publicado: (2020)

USP1 links platinum resistance to cancer cell dissemination by regulating Snail stability
por: Sonego, Maura, et al.
Publicado: (2019)

Genetic characterization of p27(kip1) and stathmin in controlling cell proliferation in vivo
por: Berton, Stefania, et al.
Publicado: (2014)

p27(kip1) expression limits H-Ras-driven transformation and tumorigenesis by both canonical and non-canonical mechanisms
por: Pellizzari, Ilenia, et al.
Publicado: (2016)

Stathmin regulates mutant p53 stability and transcriptional activity in ovarian cancer
por: Sonego, Maura, et al.
Publicado: (2014)

Stathmin regulates mutant p53 stability and transcriptional activity in ovarian cancer
por: Sonego, Maura, et al.
Publicado: (2013)

CDK4/6 Inhibitors in Combination Therapies: Better in Company Than Alone: A Mini Review
por: Rampioni Vinciguerra, Gian Luca, et al.
Publicado: (2022)

Time-tuning cancer therapy
por: Baldassarre, Gustavo, et al.
Publicado: (2015)

STAT3 in Breast Cancer Onset and Progression: A Matter of Time and Context
por: Segatto, Ilenia, et al.
Publicado: (2018)

Surgery-induced wound response promotes stem-like and tumor-initiating features of breast cancer cells, via STAT3 signaling
por: Segatto, Ilenia, et al.
Publicado: (2014)

Loss of p27(kip1) increases genomic instability and induces radio-resistance in luminal breast cancer cells
por: Berton, Stefania, et al.
Publicado: (2017)

HMGA1 positively regulates the microtubule-destabilizing protein stathmin promoting motility in TNBC cells and decreasing tumour sensitivity to paclitaxel
por: Sgubin, Michela, et al.
Publicado: (2022)

p70S6 kinase mediates breast cancer cell survival in response to surgical wound fluid stimulation
por: Segatto, Ilenia, et al.
Publicado: (2014)

A new role for IDH1 in the control of ovarian cancer cells metabolism and senescence
por: Sonego, Maura, et al.
Publicado: (2020)

TIMP-1 Is Overexpressed and Secreted by Platinum Resistant Epithelial Ovarian Cancer Cells
por: Sonego, Maura, et al.
Publicado: (2019)

Landscape of CDKN1B Mutations in Luminal Breast Cancer and Other Hormone-Driven Human Tumors
por: Cusan, Martina, et al.
Publicado: (2018)

Role of T198 Modification in the Regulation of p27(Kip1) Protein Stability and Function
por: Schiappacassi, Monica, et al.
Publicado: (2011)

Preclinical validation of a novel compound targeting p70S6 kinase in breast cancer
por: Segatto, Ilenia, et al.
Publicado: (2016)

Stathmin Is Dispensable for Tumor Onset in Mice
por: D’Andrea, Sara, et al.
Publicado: (2012)

Loss of CDKN1B induces an age‐related clonal hematopoietic disorder via Notch2 activity dysregulation
por: Segatto, Ilenia, et al.
Publicado: (2023)

p27kip1 at the crossroad between actin and microtubule dynamics
por: Rampioni Vinciguerra, Gian Luca, et al.
Publicado: (2019)

TP53 status and taxane-platinum versus platinum-based therapy in ovarian cancer patients: A non-randomized retrospective study
por: Kupryjanczyk, Jolanta, et al.
Publicado: (2008)

CDKN1B mutation and copy number variation are associated with tumor aggressiveness in luminal breast cancer
por: Viotto, Davide, et al.
Publicado: (2020)

The Consequence of Oncomorphic TP53 Mutations in Ovarian Cancer
por: Brachova, Pavla, et al.
Publicado: (2013)

HSP90 identified by a proteomic approach as druggable target to reverse platinum resistance in ovarian cancer
por: Lombardi, Rita, et al.
Publicado: (2021)

TP53 oncomorphic mutations predict resistance to platinum- and taxane-based standard chemotherapy in patients diagnosed with advanced serous ovarian carcinoma
por: BRACHOVA, PAVLA, et al.
Publicado: (2014)

Survival of patients with structurally-grouped TP53 mutations in ovarian and breast cancers
por: Seagle, Brandon-Luke L., et al.
Publicado: (2015)

Expression signatures of TP53 mutations in serous ovarian cancers
por: Bernardini, Marcus Q, et al.
Publicado: (2010)

The TP53 website: an integrative resource centre for the TP53 mutation database and TP53 mutant analysis
por: Leroy, Bernard, et al.
Publicado: (2013)

Optimized p53 immunohistochemistry is an accurate predictor of TP53 mutation in ovarian carcinoma
por: Köbel, Martin, et al.
Publicado: (2016)

LINC01605 Is a Novel Target of Mutant p53 in Breast and Ovarian Cancer Cell Lines
por: Coan, Michela, et al.
Publicado: (2023)

Enhancing cytotoxic and apoptotic effect in OVCAR-3 and MDAH-2774 cells with all-trans retinoic acid and zoledronic acid: a paradigm of synergistic molecular targeting treatment for ovarian cancer
por: Karabulut, Bulent, et al.
Publicado: (2010)

Molecular biology of breast tumors and prognosis
por: Baldassarre, Gustavo, et al.
Publicado: (2016)

Roles of CDKN1B in cancer?
por: Belletti, Barbara, et al.
Publicado: (2015)

The many facets of miR‐223 in cancer: Oncosuppressor, oncogenic driver, therapeutic target, and biomarker of response
por: Favero, Andrea, et al.
Publicado: (2021)

miR‐9 modulates and predicts the response to radiotherapy and EGFR inhibition in HNSCC
por: Citron, Francesca, et al.
Publicado: (2021)

Contact inhibition modulates intracellular levels of miR-223 in a p27kip1-dependent manner
por: Armenia, Joshua, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_hjtosm51edqsb11smmgk9idjn2